High-Content Drug Screening with Engineered Musculoskeletal Tissues

Phenotypic Drug Discovery with High Content Screening

Drug discovery in its early history used to be conducted mainly in a target-agnostic fashion, focusing on qualitative readouts from a living system -cells, tissue, or organisms -and asking the question, ‘Did this entity affect the phenotype?’. With the rise of molecular biology in the early 1980s and an ever more powerful genomics toolkit from the 1990s, there was a marked shift away from pheno...

High Content Screening in Drug Discovery

The term high content screening (HCS) has become synonymous with imaging screen using automated microscopes and automated image analysis. The term was coined a little over 10 years ago, since then the technology evolved considerably and has established itself firmly in the drug discovery and development industry. Both the instruments and the software controlling the instruments and analyzing th...

Image-Based High-Content Screening in Drug Discovery

High-Content, Image-Based Screening for Drug Targets in Yeast

BACKGROUND Drug discovery and development are predicated on elucidation of the potential mechanisms of action and cellular targets of candidate chemical compounds. Recent advances in high-content imaging techniques allow simultaneous analysis of a range of cellular events. In this study, we propose a novel strategy to identify drug targets by combining genetic screening and high-content imaging...

The application of engineered liver tissues for novel drug discovery.

INTRODUCTION Drug-induced liver injury remains a major cause of drug attrition. Furthermore, novel drugs are being developed for treating liver diseases. However, differences between animals and humans in liver pathways necessitate the use of human-relevant liver models to complement live animal testing during preclinical drug development. Microfabrication tools and synthetic biomaterials now a...